MolDx Finalizes LCD Expanding Coverage for Natera's Prospera Transplant Tests
NTRA has more than doubled off its 52-week low of $131.811.
Summary
The finalized MolDx LCD significantly expands coverage for Natera's Prospera portfolio in kidney, heart, and lung transplant surveillance. Compared to the July 2025 draft, test frequencies are materially higher: kidney surveillance now includes 6 tests in year 1 (up from 4) and 4 per year in years 2-3 (up from 2); heart and lung each get 12 tests in year 1 and 4 per year thereafter. The policy takes effect August 30, 2026. This follows strong Q1 2026 revenue growth of 38.8% and recent regulatory wins for Signatera, reinforcing Natera's reimbursement momentum. Broader coverage directly expands the addressable market for Prospera and should support higher testing volumes and revenue per patient. The backing of major transplant societies adds clinical validation.
At the time of this announcement, NTRA was trading at $270.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.6B. The 52-week trading range was $131.81 to $288.04. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.